Pulmatrix, Inc. (PULM): Total Liabilities
$329.0K
As of 2025-12-31
$689.0K
As of 2026-06-30
-67.8%
3-year compound annual growth
-53.4%
5-year compound annual growth
-30.4%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $329.0K | -67.0% | 2026-06-16, Balance as of period end |
| 2024-12-31 | $996.0K | -93.8% | 2026-06-16, Balance as of period end |
| 2023-12-31 | $15.96M | +62.2% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $9.84M | -13.4% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $11.37M | -24.0% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $14.96M | -40.4% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $25.08M | +771.1% | 2021-03-23, Balance as of period end |
| 2018-12-31 | $2.88M | -50.7% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $5.84M | -26.1% | 2019-02-19, Balance as of period end |
| 2016-12-31 | $7.90M | -35.6% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $12.27M | -72.6% | 2017-03-10, Balance as of period end |
| 2014-12-31 | $44.77M | n/a | 2016-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | 2025-12-31 | $329.0K | -67.0% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $1.57M | +30.1% |
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $1.59M | -40.8% |
| Bio-Path Holdings, Inc. (BPTH) | 2024-12-31 | $3.73M | +34.2% |
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $1.03M | -79.5% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $1.22M | -26.3% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2025-12-31 | $2.29M | -87.3% |
| Polaryx Therapeutics, Inc. (PLYX) | 2025-12-31 | $605.0K | +109.3% |
Compare PULM, LEXX, CVKD, BPTH side by side · Screen every company in Pharmaceutical Preparations ↗